TD Cowen lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $24 from $34 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals: Buy Rating Reiterated as Updated Ojemda Forecasts and DCF Support Attractive Valuation Despite Lowered Price Target
- Day One Biopharmaceuticals reinstated with a Buy at TD Cowen
- Day One Biopharmaceuticals: Ojemda Outperformance and Advancing Pipeline Support Overweight Rating
- Video: Financials weighed down by Trump attacks on Fed, credit card rates
- Morning Movers: Sun Country jumps after deal to be bought by Allegiant